Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Cuts JD HEALTH's TP to HKD66.5 But Expects Drug Sales to Continue Delivering Positive Surprises
Recommend 5 Positive 5 Negative 3 |
||||
|
||||
|
JD HEALTH (06618.HK) has announced its full-year results for the year ending December 2025, with performance in 2H25 exceeding expectations, according to CLSA's research report. The company's revenue increased by 28% YoY to RMB38.2 billion, while the adjusted EBIT rose by 88% YoY to RMB1.9 billion. CLSA expects JD HEALTH's revenue momentum to continue on the strength of pharmaceuticals, especially original prescription drugs. The 2026 revenue is estimated to grow by 18% YoY. The broker has reduced its target price for JD HEALTH from HKD71 to HKD66.5 but kept the Outperform rating unchanged. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
